We evaluated the performance of the CONFIRM anti-Ki-67 (30-9) Rabbit Monoclonal Primary Antibody in assessing the risk of distant relapses in a large series of patients with ER-positive HER2-negative breast cancer treated and followed up in a single Institution. This evidence concerns the gene ESR1 and breast carcinoma.